Waite Enterprise CEO Daniel Waite Announces Roll Out of Unique All Natural Medical Marketing Platform Live Well Organix

Waite Enterprise has expanded subsidiary CBD Organix into Wellness Organix LLC, with a new Network called Live Well Organix

DALLAS, TX, USA, April 30, 2019 /EINPresswire.com/ — DALLAS, TX – CEO Daniel Waite is proud to announce that Waite Enterprise has expanded upon the initial offerings of CBD Organix, a holistic medical company recently deployed to help ease the suffering of many millions of chronic pain sufferers. That company initially offered patients suffering from many diseases and disorders, from dementia to cancer, a unique CBD based topical cream. The cream helped fight pain, swelling, inflammation and irritations brought about by all kinds of issues.

This treatment that was brought to market by CBD Organix is a natural, non-addictive, safe treatment that simply helps improve the quality of life of many sick and suffering people worldwide. However, the company has expanded its horizons and grown into Wellness Organix, LLC, (DBA as Live Well Organix) a unique all natural medical marketing company that will provide more than one type of treatment.

“Wellness Organix, LLC is a completely unique medical MLM that will revolutionize the industry, offering natural, safe, non-narcotic methods of treating pain and irritation to many, many people who have suffered far too much for far too long.” Waite explains. “Live Well Organix will be a direct sale company that will recruit members as returning customers and brand ambassadors. They in turn will recruit more ambassadors and more customers.”

Most importantly they will be offering a series of treatments, services and products that will help people who are in dire need of relief in a safe and effective manner. This is the easiest, quickest, and most cost effective method to bring to market safe, non-narcotic alternatives for people who are in constant pain. Live Well Organix will be a one stop, self-propelling shop that delivers itself through a growing network of ambassadors to many patients who otherwise would have no alternative but addictive narcotic treatments.

About Waite Enterprise:

Waite Enterprise (subsidiary of Waite Capital, Inc.) is a diversified holding company with a vast platform of subsidiaries and investments that leverage resources and growth from various sectors, currencies and assorted commodities, from cryptocurrency to real estate to high end vehicles. The company is being developed by Daniel Waite with the intention of ultimately going public, offering a diversified investment platform designed as a basket that provides revenue streams from digital platforms, currencies, and businesses in the construction, healthcare and financial fields.

About Wellness Organix LLC:

Wellness Organix, LLC is a Holistic medical marketing company with a DBA called Live Well Organix, both located in Texas. Live Well Organix is a revolutionary network marketing wellness brand that provides therapeutic services and products for customers suffering from a myriad of illnesses and serious debilitating diseases.

don eminizer
Smoulder Pro
717-387-5149
email us here


Source: EIN Presswire

Calcium in Arteries is Shown to Increase Patients’ Imminent or Long-Term Risk of a Heart Attack, Researchers Find

test

New study from the Intermountain Healthcare Heart Institute in Salt Lake City shows that identifying the presence or absence of coronary artery calcium in a patients’ arteries can help determine their future risk.

Through these results, we’re seeing more clearly that the presence of coronary artery calcium can help us to predict who is more likely to have a cardiac event.”

— Viet Le, PA-C, Intermountain Healthcare Heart Institute

SALT LAKE CITY, UTAH, 84111, April 30, 2019 /EINPresswire.com/ — About six million people come into an emergency department every year with chest pain, but not all of them are having a heart attack — and many are not even at risk or are at very low risk for having one.

Now, a new research study presented at the American College Cardiology Scientific Sessions from the Intermountain Healthcare Heart Institute in Salt Lake City shows that identifying the presence or absence of coronary artery calcium (CAC) in a patients’ arteries can help determine their future risk.

“Through these results, we’re seeing more clearly that the presence of coronary artery calcium can help us to predict who is more likely to have a cardiac event, not only later in life, but when symptoms are present, in the near future and hopefully, medically intervene in time to stop it,” said Viet T. Le, PA-C, principal investigator and researcher at the Intermountain Healthcare Heart Institute in Salt Lake City.

Results of the study were presented at the American College of Cardiology Scientific Sessions last month in Atlanta.

For the study, researchers identified 5,547 patients without a history of coronary artery disease who came to Intermountain Medical Center with chest pain between April 2013 and June 2016.

These patients had undergone PET/CT scans to assess for ischemia, a disruption of normal blood flow through the heart arteries to the muscle tissues of the heart. This scan also looks for the presence of CAC, which are calcium deposits on the walls of the heart’s arteries, indicating atherosclerosis, or plaque, the hallmark of heart disease. The researchers then examined patients’ medical outcomes for up to the next four years.

Researchers found that patients whose scans revealed CAC were at higher risk of having a heart event within 90 days compared with patients whose PET/CT showed they had no CAC. Researchers also found that patients with CAC were also more likely over the following years to have high-grade obstructive coronary artery disease, revascularization surgery, and/or other major adverse cardiac events than patients who had no coronary artery calcium.

The findings can be used in two different ways, said Le.

First, testing for CAC can help emergency departments quickly identify those patients with chest pain, but are not in acute distress as being at risk for a future heart event from those who may have non-heart related symptoms and should follow up with their primary care physician to identify the true source of the chest pain, which may be as simple as a pulled muscle. These CAC scans are non-invasive, use only as much radiation as a mammogram, and are relatively cheap, especially compared to PET/CT stress tests, Le said.

Second, CAC isn’t easily visually identifiable at low or moderate levels in the arteries without a formal scan. Checking patients who are not actively found to be experiencing a heart event but who have suspicious symptoms when they come to the ED can help physicians identify who is at risk for a future event. This allows for early initiation of risk reducing lifestyle changes in those found to have CAC to avoid future events.

“We can have that discussion about improving their lifestyle a little sooner this way because they may not be having an acute event but they’re looking down the barrel of one, so let’s see if we can move that barrel away,” said Le.

Future studies are needed to demonstrate whether a CAC first strategy in these symptomatic patients will better identify those who should have further stress testing as well as improve patient education and early implementation of risk reducing strategies.

This research was funded by the Intermountain Foundation.

Jess C. Gomez
Intermountain Healthcare
+1 801-718-8495
email us here


Source: EIN Presswire

First Drug Discovered in a Fruit Fly Used in Cancer Patients

Drug developer Tosk, Inc.,

Innovative drug developer Tosk designs drug to eliminate painful, life-threateningl side effects of front-line cancer therapies

Our scientists have developed two proprietary drug discovery platforms that use fruit flies to identify new drugs to combat cancer and other diseases.”

— Brian Frenzel, CEO, Tosk, Inc.

MOUNTAIN VIEW, CALIFORNIA, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Drug developer Tosk, Inc. announced today that its patented drug, TK-90, which prevents the adverse side effects of frontline cancer therapies, succeeded in human clinical studies involving 25 head-and-neck cancer patients. TK-90 is the first drug discovered through screening using the common fruit fly (Drosophila melanogaster) to be tested in patients. The drug prevents mucositis, a painful, dose limiting, side effect suffered by many cancer patients undergoing chemotherapy and radiation therapy.

“Fruit flies have played an important role in scientific research for generations,” said Brian Frenzel, Tosk’s CEO, pointing out that six Nobel prizes in medicine or physiology have been awarded to scientists based on their research using the fruit fly, the latest in 2017. “However,” he added, “Drosophila have not been widely used for drug discovery and development by the pharmaceutical industry. Tosk is an exception. Our scientists have developed two proprietary drug discovery platforms that use fruit flies to identify new drugs to combat cancer and other diseases.”

Tosk, like the Nobel prize winners, uses the fruit fly because it has surprising similarities to humans at the genetic and molecular levels. Adult fruit flies, for example, have body parts that mimic mammalian hearts, kidneys, digestive tracts, and lungs. Nearly 70 percent of human disease-related genes have analogs in the fruit fly. “Because the life cycle of a fruit fly is short, only 50 days from birth to death and only two weeks from birth to adulthood, drug discovery in flies can be done quickly and cost effectively,” Frenzel says. “Using non-mammals as a discovery tool may yield new drugs that could not have been found using other, more traditional methods.”
Tosk selected TK-90 out of tens of thousands of compounds using what the company calls the Side Effect Fly™. Tosk incubates test compounds with a toxic chemotherapeutic that would otherwise prevent eggs from hatching and developing. Compounds that increase survival and result in larvae or mature fruit flies are "hits." Hits are tested in cell culture models using human cancer cells to select "leads" that do not affect the cancer killing efficacy of the chemotherapy. Tosk’s researchers then move to traditional models to confirm safety, adverse effect prevention, and non-interference with the beneficial effects of the cancer therapy.
“Instead of picking a target and fitting compounds to match, as most pharmaceutical companies do, our scientists let the fruit fly tell us which compounds are safe and effective. We then work backward to identify the molecular target or targets through which the drug works, opening what we believe is an exciting new vista on the process of drug discovery.”

Tosk has innovated a second, perhaps even more important, drug discovery platform, which it calls the Genetically Modified Fly™. Tosk integrates a human disease gene into Drosophila and then tests compounds for their ability to block the activity of the disease gene. This model is designed to discover drugs for disease targets that have previously been considered “undruggable.”

In addition to TK-90, Tosk has three other new drugs in its pharmaceutical development pipeline. The most advanced is TK-39, which prevents the dose-limiting, permanent, and potentially fatal damage to the heart caused by doxorubicin and other widely used, frontline cancer therapies. Another side effect preventing drug is TK-88, which prevents permanent kidney damage caused by platinum-based drugs such as carboplatin and cisplatin. Both were discovered using the Side Effect Fly.
Tosk’s “cancer moonshot” program addresses a top priority for the U.S. National Cancer Institute (NCI), developing a drug to block the activity of the human kRAS cancer gene. Funded by a $2 million grant from NCI, Tosk has used its Genetically Modified Fly for this purpose. The mutant kRAS gene drives as many as 30 percent of all cancers, including 90 percent of pancreatic, 45 percent of colon, and 35 percent of lung cancers.

Tosk’s fruit fly based drug screening technologies afford a new method to find small molecule, inexpensive drugs for difficult targets. “We think our fly models give us an advantage, a way to succeed where others have failed,” Frenzel says. Tosk’s first drug candidate, TK-90, has confirmed this in human clinical studies. Tosk believes that this is just the beginning, and plans to deliver many more drugs to improve outcomes for cancer patients.

Tosk, Inc. is a privately held biopharmaceutical company that develops new drugs to prevent the adverse side effects of existing, widely-used cancer therapies and to block the activity of cancer genes. For further information on the company, see www.tosk.com.

Brian Frenzel
Tosk, Inc.
+1 408-245-6838
email us here


Source: EIN Presswire

Innovative Household Cleaner Fights Bacteria for 24 Hours

BYOTROL24 is scientifically proven to work for 24 hours.

BYOTROL24 Disnifectant Cleaner PLUS 24-Hour Surface Sanitizer, Lavender Morning 24-Hour Fragrance

Byotrol24 Now Available at Target

Byotrol (.:BYOT.L)

This innovative cleaning product is a scientific breakthrough in germ control, the only household cleaner that controls bacteria for 24 hours.”

— Alex Espalin

ATLANTA, GA, USA, April 30, 2019 /EINPresswire.com/ — With a standard disinfectant cleaner, germs can re-contaminate treated surfaces within just minutes. A swipe of a dirty hand or a wayward sneeze is all it takes to re-introduce germs to a clean surface. Germs can then survive on surfaces for hours or even days. Now, an advanced new cleaner — Byotrol24™ —not only kills over 99.9% of germs but also keeps eliminating new bacteria on surfaces all day long, even after multiple touches.

Byotrol24 (www.Byotrol24.com) is available at select Target stores and online at Target.com and Amazon.com. Two new Byotrol24 scents — Lavender Morning™ 24-hour fragrance and Hawaiian Sunrise Citrus™ 24-hour fragrance — were introduced this week at Target. These fragrances are designed to last for 24 hours to provide a sensory cue that Byotrol24 is working around the clock to eliminate over 99.9% of bacteria.

Byotrol24 eliminates Flu and Cold viruses, E. coli, Salmonella, Staph, Strep, Listeria, Pseudomonas Aeruginosa and other germs. Of particular note is this product’s ability to kill Norovirus, a deadly virus especially difficult to kill. Norovirus contributes to 71,000 hospitalizations each year, according to the CDC. In addition, what makes Byotrol24 revolutionary and unique is its patented cleaning formula that is scientifically proven by independent testing to keep surfaces sanitized for 24 hours with just one treatment.

Whereas many standard cleaners today can be harsh on surfaces as well as slightly or moderately toxic to people and pets, Byotrol24 is a non-harsh disinfectant and surface sanitizer that emits no chemical fumes and even requires no gloves to use. Byotrol24 is ideal for use on household surfaces, especially those that are frequently touched – door handles, refrigerator handles, sinks and sink handles, kids’ toys, toilets and toilet handles, for example.

In addition, Byotrol24 is ideal for eliminating harmful microbes in work spaces, such as desks, phones, conference tables, elevator buttons and other surfaces. Researchers at the University of Arizona found that just one contaminated door handle can spread germs to 40-60% other “high-touch” surfaces in the office within only 2 to 4 hours.

“We are excited to introduce our Lavender Morning and Hawaiian Sunrise Citrus scented Byotrol24 cleaners at Target,” said Alex Espalin, chief marketing officer for Byotrol. “This innovative cleaning product is a scientific breakthrough in germ control, the only household cleaner that controls bacteria for 24 hours. Byotrol24 will make a positive difference in people’s lives to help stop the spread of germs.”

About Byotrol
Byotrol is devoted to the development of innovative antimicrobial solutions that improve upon traditional cleaning and sanitizing methods. Headquartered in a university research park near Manchester, England, Byotrol has a global reach that extends from Europe to North America, Asia and South Africa. A wide range of branded and licensed technologies and products span both the consumer and professional segments. The company’s U.S. operating division, Byotrol Inc., is based in Atlanta. For more information, visit www.byotrol24.com.

###

.
Byotrol Inc.
.
email us here


Source: EIN Presswire

John LaChance Joins Cascade Thermal as Vice President of Technology

John LaChance, Cascade Thermal Vice President of Technology

With this team, consultants have unprecedented access to thermal remediation capabilities under one roof.”

— John LaChance, Cascade Thermal Vice President of Technology

BOTHELL, WASHINGTON, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Cascade Thermal, a leader in the development and implementation of in situ and on‐site thermal remediation of toxic contaminants, announces the appointment of thermal remediation expert John LaChance as Vice President of Technology.

LaChance’s environmental remediation career spans over 30 years, specializing in hydrogeology and in situ thermal remediation to address challenging site hydrogeologic and contaminant conditions. He previously served as Vice President of Hydrogeology at TerraTherm for twelve years before launching the Arcadis Thermal Remediation program in 2013, where he served as their Global Thermal Practice Lead. Most recently, John served as President of Mc2 USA Inc., A Division of McMillan-McGee Corp.

“We are extremely pleased to welcome John back to his thermal remediation roots,” said Peter Palko, Executive Vice President of Operations. “In addition to his extensive global experience with all three thermal technologies, John has a broad range of groundwater remediation experience capable of supporting Cascade’s full suite of site investigation and environmental remediation services.”

“I’m honored to join this prestigious team of talented remediation professionals,” said LaChance. “With this team, consultants have unprecedented access to thermal remediation capabilities under one roof. The broad range of practical field application of thermal, chemical, and bioremediation technologies brings customized, cost-effective solutions for any project site.”

About Cascade Thermal
Cascade Thermal is a leader in the development and implementation of in situ and on‐site thermal remediation of toxic contaminants. Cascade Thermal designs, builds and operates projects from concept to completion, using Thermal Conduction Heating (TCH), Steam Enhanced Extraction (SEE), Electrical Resistance Heating (ERH), and combinations of the technologies above. With more than 80 full time staff, the combined forces of these groups represent the most experienced team in the thermal remediation industry. Cascade Thermal is part of the Cascade Environmental family of brands. Learn more about Cascade’s full suite of drilling, site characterization, and remediation services at www.cascade-env.com.

Sue Bruning
Cascade Environmental
+1 567-202-3525
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Cloud Pharmaceuticals to Present AI-Based Drug Design at Conferences in May

Cloud Pharmaceuticals is a leader in the design of new drugs using Artificial Intelligence

Don Van Dyke, COO Cloud Pharmaceuticals

COO Don Van Dyke to describe company technology and achievements in designing small molecule and peptide agents.

We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance”

— Don Van Dyke

RESEARCH TRIANGLE PARK, NC, UNITED STATES, April 30, 2019 /EINPresswire.com/ — Don Van Dyke, COO of Cloud Pharmaceuticals Inc., an AI-based drug design company, is being featured as a speaker at several conferences in May. Van Dyke will discuss how Artificial Intelligence-based drug design is helping to transform the creation of new medicines.

During his sessions, Van Dyke describe Cloud Pharmaceuticals’ Quantum Molecular Design process, which enables faster progress at lower cost and a higher success rate than traditional methods, even with difficult targets. He will reference the company’s work with companies such as GSK to advance from target to lead molecule in months rather than years.

Schedule:

4th Drug Discovery Nexus Summit 2019 May 16-17, 2019, Boston, MA.

8th DRUG DISCOVERY INNOVATION PROGRAMME May 21, 2019
Boston, MA

PHARMA AI May 23 – 24, 2019 London, UK

“We are at the threshold of a revolution in medicine that will be more dramatic than any prior advance,” Van Dyke explains. “Designed drugs may be similar to discovered natural compounds, which will continue to give scientists clues about how nature and evolution have shaped biological interactions. But deeper understanding of the molecular basis for disease will bring about targeted attacks on the functioning of the very molecules that make us sick.”

Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new medicines. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications. For information visit www.cloudpharmaceuticals.com.

Irene Shipley
Cloud Pharmaceuticals
+1 984-329-2388
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

The Flu Shot – a few more good reasons to get one – new article by Pediatrician Dr. Kenneth Rebong

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Dr Kenneth Rebong, medical doctor, California

Every year there seems to be the same discussion, whether or not to get a flu shot. Pediatrician Kenneth Rebong, MD, explains in a new published article.

Kenneth Pomar Rebong, MD (N/A:N/A)

While the CDC recommends that anyone older than 6 months get the flu shot, including pregnant women and people with chronic health conditions, there are exceptions”

— Dr. Kenneth P Rebong, pediatrician

SAN JOSE, CALIFORNIA, UNITED STATES, April 29, 2019 /EINPresswire.com/ — The flu shot discussion starts again every year when flu season starts. It is true that there are many different strains of the influenza virus and the vaccine might not necessarily protect you from getting the flu. However, the big picture is that if many get the flu shot, it will lower the overall rate flu infection. So, consider getting a flu shot not just for you, but for the people around you. Dr. Kenneth Rebong, MD, based in San Jose, California, provides his thoughts on this issue. The complete article is available on the Blog of Dr. Rebong at https://drkennethrebong.wordpress.com/

As usual, with all health issues, any questions or concerns should be discussed with your primary care doctor to make an informed decision. The flu shot is not for everybody, and it should be age appropriate. Your doctor can review your medical history and provide personalized advice. Also, the Centers for Disease Control and Prevention (CDC) maintain a website with detailed information about the flu shot, and related information. See https://www.cdc.gov/flu/protect/keyfacts.htm.

Our society generally tends to underestimate the seriousness of the flu and consider it similarly to the common cold. This is a common misconception. The Influenza virus is considerably more serious in nature. The CDC estimates that the flu has caused between 140,000 to 710,000 hospitalizations and as many as 12,000 and 56,000 deaths annually in the U.S. since 2010. Annual flu vaccine is the first step towards gaining protection against this disease and the CDC recommends it for everyone who is 6 months of age and older.

Consequences of the Flu

Typically, flu viruses start with infection to your nose, throat and lungs, but it can go on to cause a wide range of complications. While sinus and ear infections are moderate complications, Pneumonia is a serious flu complication that arises either due to the flu infection itself or if you’re simultaneously infected by bacteria as well as the flu virus.

Other more serious complications can include inflammation of the heart, brain or muscle or even multi-organ failure. An extreme inflammatory response can result in sepsis. In the past seven flu seasons, influenza vaccination prevented around 5.3 million illnesses and 85,000 hospitalizations and as per the CDC a mere 5% increase in the number of vaccinations could have further prevented as many as 483,000 influenza illnesses. It would have stopped another two hundred thousand plus influenza-associated medical visits, and around seven thousand influenza-associated hospitalizations across the U.S.A.

Some are more at risk than others

While anyone can get the flu, some people are at higher risk of a more severe form of infection. These include:
* Children younger than 5 years old, particularly those that are younger than 2 years old
* People older than 65 years old
* People suffering from asthma or chronic lung disease
* People with neurological conditions, heart disease and those suffering from blood, liver, kidney, endocrine and metabolic disorders
* People whose immune system has recently been compromised due to an illness
* Pregnant women

Does the flu shot really work?

Because there are different strains of the influenza virus each year, the flu vaccine is modified every year to target the particular strain that is predicted to circulate that year. However, there is no way of knowing which strain it might be. Thus, the effectiveness of the vaccine somewhat depends on how accurate the predictions are. Despite this, the CDC still strongly recommends that you get the flu vaccine as it still offers some degree of protection even if it’s not completely effective in preventing the disease. Because the influenza virus is transmittable, if a fewer number of people get sick, then the virus won’t be able to penetrate as deeply and spread. Besides CDC, other professional medical groups like the American Academy of Pediatrics, the National Foundation of Infectious Diseases and the American Medical Association also recommend an annual flu vaccine.

There are several options for the 2018-2019 flu season, these include:
* Standard dose flu shots given into the muscle. A needle is used to inject these, but for some people between the ages of 18 and 64 years old, a jet injector can be used.
* Shots made with adjuvant. These are suitable for older people.
* Shots made the help of virus previously grown via cell culture technique.
* Shots made using vaccine production technology. These do not employ the flu virus and follow a different mechanism.
* The nasal spray vaccine, also known as the live attenuated influenza vaccine (LAIV). This is recommended for use in non-pregnant individuals between the ages of 2 and 49 years. People with underlying medical conditions are advised against using the nasal spray flu vaccine.

What about side effects?

The influenza vaccine is formulated from an inactivated or weakened version of the influenza virus so you might experience flu-like symptoms post vaccination. These will subside however, and you won’t suffer from a full bout of the flu. There may also be some redness or swelling at the injection site, and low-grade fever. The side-effects are not really a concern because it just means that the vaccine is working and will be able to protect you from the actual virus.

The immunity from the previous year’s flu shot work will not be sufficient. First, the immune response generated by last year’s vaccine has gradually declined. Therefore, you need to be injected with a new one for continued protection. Also, as discussed above, the flu virus is constantly changing in strain. The flu vaccine is also analyzed accordingly and redesigned to combat new forms of the virus each year.

Too busy to get a flu shot?

Flu vaccines are easily available at many different locations such as doctor’s offices, clinics, pharmacies and college health centers. Many employers and schools offer them as well. It is recommended to get a flu shot before the virus starts spreading in your community as it takes around 2 weeks for your body to build up a sufficient immunity. If you’re looking to get one, it is best not to wait around and get one as soon as possible to ensure maximum protection.

Is it right for everybody?

As mentioned earlier, when in doubt, discuss it with your primary care doctor. While the CDC recommends that anyone older than 6 months get the flu shot, including pregnant women and people with chronic health conditions, there are exceptions. You should avoid the flu shot if you’re severely allergic to the components in the flu shot. Also, if you have ever had the Guillan-Barré Syndrome (An immune disorder), then consult your doctor before getting a flu shot.

One of the components involved in the manufacturing of flu vaccines are eggs, but as per the CDC, even if you suffer from egg allergies, you can still get the flu shot. In case your allergies are serious and you are concerned side effects from vaccinations, please consult your doctor.

About Dr. Kenneth P. Rebong

Dr. Kenneth Pomar Rebong, MD, a medical doctor in San Jose, California, and specializes in Pediatrics and Adolescent Medicine. He completed his Pediatric Residency at Rutgers University in New Brunswick, New Jersey.

https://medicogazette.com/dr-kenneth-pomar-rebong
https://hippocratesguild.com/dr-kenneth-pomar-rebong
https://drkennethrebong.wordpress.com/
https://www.linkedin.com/in/kenneth-pomar-rebong-md-4484a938/

Kenneth Pomar Rebong, MD
Kenneth Pomar Rebong, MD
+ +1 408-729-3232
email us here
Visit us on social media:
LinkedIn

Mayo Clinic Minute: The facts about 3 flu vaccine myths


Source: EIN Presswire

Plastic Surgeon Dr. Tansar N. Mir starts Blog about plastic surgery issues

Website of Dr Tansar N Mir, New York

Website of Dr Tansar N Mir, New York

Dr Tansar N Mir, New York, on Dr Oz Show

Dr Tansar N Mir, New York, on Dr Oz Show

Dr Tansar Mir, New York, on television show The Doctors

Dr Tansar Mir, New York, on television show The Doctors

Dr Tansar Mir, New York, on television show The Doctors

Dr Tansar Mir, New York, on television show The Doctors

Dr Tansar Mir operating on a patient in a publicized case, photograph by Susan Watts, New York Daily News

Dr Tansar Mir operating on a patient in a publicized case, photograph by Susan Watts, New York Daily News

Experienced surgeon’s blog will address diverse issues in plastic & reconstructive surgery, such as how to promote better healing after surgery.

Tansar Mir, MD – Plastic & Reconstructive Surgery (N/A:N/A)

One should not act based solely on medical information found on the internet, but instead review with a qualified medical doctor, preferably with the benefit of the patient’s medical history.”

— Dr. Tansar N. Mir, Plastic Surgeon in New York

NEW YORK, NEW YORK, UNITED STATES, April 29, 2019 /EINPresswire.com/ — Doctor Tansar N. Mir, an experienced plastic & reconstructive surgeon based in New York, started a Blog to provide easy-to-understand information about the plastic surgery issues so that the public and patients can easily understand the underlying medical issues and procedures. The Blog is available at https://tansarmirmd.home.blog/

Americans spend billions of dollars every year on plastic surgery. Many people try to enhance their appearance or correct what they perceive to be malformed. Common procedures include breast augmentation, rhinoplasty, and liposuction. There are, however, certain risks associated with such procedures. Thus, researching the specific surgery that you have in mind for yourself is a good idea. Also, make sure to be in good hands, meaning a qualified surgeon with experience in this particular procedure. Some commonly occurring issues in plastic surgery include:

Dissatisfaction with the result – plastic surgery is not an exact science and the results may differ depending on many different factors such as age, gender, body type, body weight, and skin condition.

Nerve Damage – a common issue in all plastic surgeries. The negative effects include numbness and tingling.

Infection – also a common issue in all plastic surgeries. While utmost care is taken to avoid infection, it occurs in a few percent of plastic surgeries and may require additional medication, for example with antibiotics.

Scars – plastic surgeons are trained to keep the scars to a minimum, but they are usually unavoidable. In some cases, patients suffer hypertrophic scarring, meaning that the scar is unusually red and raised.

Hematoma – which is essentially a pocket of blood resembling a painful bruise. A hematoma occurs in a few percent of breast augmentation surgeries, and also after a facelift. Hematoma a general risk in plastic surgery, and it may sometimes require additional surgery.

Organ Damage – some surgeries may adversely affect internal organs, such as liposuction. The surgical probe used for liposuction may accidentally cause punctures, which may require additional surgery.

Seroma – a condition when blood pools directly under the skin, with swelling and pain. These can become infected and may have to be drained.

Blood Loss – occurs in most plastic surgeries, but is usually limited. If there is an uncontrolled blood loss, it can result in a sudden drop in blood pressure and even result in death. Note, however, that such blood loss can also occur internally.

Anesthesia – thanks to anesthesia, the bodily pain of plastic surgery is greatly reduced, yet it has the potential for complications. For example, general anesthesia renders patients unconscious, but can lead to issues such as stroke and heart attacks.

Deep vein thrombosis (DVT) – is a rare complication. Essentially, it means that a blood clots forms in a deep vein (often the leg), breaks off, and travels to other parts of the body (such as the lungs, causing pulmonary embolism).

Dr. Mir explains that “even though it is particularly important for this type of medical treatment, in today’s plastic surgery practices, nurses, staff and medical doctors are rushed and rarely have the time to answer all questions that the patients have. That’s when patients start researching on the internet. They find opinions, reports from other patients, but rarely explanations from medical doctors. One should not act based solely on information found on the internet, but instead review the issues with a qualified medical doctor, preferably with the benefit of the patient’s medical history. Also, when patients research online and do find relevant medical articles, they find highly complex answers that are very difficult to understand for a layperson, or even contradictory. I hope to fill that information gap with explanatory articles that anybody can understand.”

Dr. Mir’s blog is available at https://tansarmirmd.home.blog/

About Dr. Tansar Naveed Mir

Dr. Tansar Mir is a plastic & reconstructive surgeon in New York. Dr. Mir received his Doctorate of Medicine with Recognition in Research from the State University of New York at Stony Brook School of Medicine after graduating from Franklin & Marshall College in Lancaster, Pennsylvania with his Bachelor of Arts in Neuroscience. Dr. Mir completed his internship and residency in General Surgery at Lenox Hill Hospital, New York, NY and his residency/fellowship in Plastic & Reconstructive Surgery with the Long Island Plastic Surgical Group through Nassau University Medical Center. Dr. Mir is a double board-certified Plastic and Reconstructive Surgeon who is certified by the American Board of Surgery and the American Board of Plastic Surgery.

References:

https://www.linkedin.com/in/tansarmir/
https://tansarmirmd.home.blog/
https://medicogazette.com/dr-tansar-n-mir%2C-ny
https://hippocratesguild.com/dr-tansar-n-mir
https://www.doctoroz.com/episode/caught-act-oz-investigates-butt-enhancement-black-market?video_id=4752832053001

Dr. Tansar N. Mir
Tansar Mir, MD – Plastic & Reconstructive Surgery
+1 212-606-8150
email us here
Visit us on social media:
LinkedIn

The Doctors Television Show: Dakota who was disfigured by black market silicone butt injections. Dr. Tansar Mir performs her silicone removal surgery


Source: EIN Presswire

Scrambler Therapy® – 3432 건의 만성 신경 병적 및 종양학 통증 분석을 포함한 과학 기사.

ROME, ITALY, April 29, 2019 /EINPresswire.com/ — 과학 저널 "Integrative Cancer Therapies (통합적 종양 치료 요법)" 는 최근에 "게이트 제어 이론 (Gate control theory) 에서 정보의 유효 원리에 이르기까지 Scrambler Therapy, 만성 신경 병적 및 암 통증의 비 침습적 치료법" 이라는 과학 논문을 발표했습니다.

이 색인 된 기사는 Scrambler Therapy® 가총 3432 가지 사례에 이르는 만성 신경 병적 및 종양 통증의 미치는 영향을 연구합니다. 이 기사에서는 Scrambler Therapy® 이론, 방법, 기술 및 임상 시험에서의 편향된 효과와 이를 최소화하는 방법을 검토합니다.

이 기사는 특히 다음과 같은 경우에 유용합니다.
– 장치의 특수하고 고유한 특성을 평가해야 하는 보건 당국.
– 건강 보험 회사는 환자를위한 비용 면제 프로그램에 추가할 치료를 고려하는 건강 보험 회사.
– 최소한의 편견으로 방법론적의 정확한 연구를 수행하고자 하는 독립적인 임상 연구자.
– Scrambler Therapy®를 최대한 활용하고자하는 의사

이 기사는 다음 주소에서 자유롭게 다운로드 할 수 있습니다. https://journals.sagepub.com/doi/10.1177/1534735419845143

통합 암 치료법에 대하여
Integrative Cancer Therapies (ICT) 는 과학 표집 색인 (Science Citation Index) SCOPUS, MEDLINE 에서 받아들여진 기사의 공개 검토 저널이며 COPE의 회원입니다.

델타 국제 서비스 및 물류 (DIS&L) 정보
DIS&L은 Scrambler Therapy® Technology (국제 특허) 의 세계적 개발 및 전 세계적 의료 기기 유통 업체 선정을 위해 창설 된 기관입니다. DIS & L은 자사의 법률 회사를 통해 국제적 독점 계약을 체결하고 사용 방법 교육 및 기타 물류 요구 사항에 대한 유지 보수 및 배급자 지원을 제공할 수있는 유일한 회사입니다.
추가 정보를 얻으려면: https://www.st-team.eu

Scrambler Therapy® (스크램블러 테라피) 기술 정보
Scrambler Therapy® 과학 연구 및 개발 기술은 지적 재산권의 유일한 소유자인 Giuseppe Marineo 교수가 이탈리아에서 개발했습니다. 공식 "Scrambler Therapy®" 과학 및 임상 정보 웹 사이트는 https://www.scramblertherapy.org/english.htm
에 있습니다.

Mariella Giorgieri
Delta International Services & Logistics s.r.l.
+39 3921603399
email us here


Source: EIN Presswire

Inmedix introduces immuno-autonomics to the 2019 Life Science Innovation Northwest Conference

A novel approach to management of rheumatoid arthritis (RA) and other autoimmune diseases.

NORMANDY PARK, WA, USA, April 28, 2019 /EINPresswire.com/ — Seattle-based medtech/biotech Inmedix, Inc. was selected to present at the 2019 Life Science Innovation Northwest conference (LSINW) held at the Washington State Convention Center in Seattle, WA. LSINW is the largest annual life science event in the Pacific Northwest and is sponsored by Life Science Washington, an independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. The conference “brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling technology breakthroughs of our time.”

Inmedix is defining the emerging medical field of immuno-autonomics: the interface between immune function and stress, controlled within the brain by the autonomic nervous system (ANS). Stress response can beneficially impact immune function in the short term. However, chronic activation of the immune system by stress, mediated by the ANS, has been implicated in adversely affecting the onset and severity of autoimmune disease.

With its ANS Neuroscan™ diagnostic in development, Inmedix seeks to eventually quantify ANS stress as a factor affecting immune function, disease severity and treatment outcome in patients with autoimmune diseases.

“As a hometown supporter of Seattle life science innovation, Inmedix was honored to be provided an opportunity to explain the concept of immuno-autonomics,” said Andrew J. Holman, MD, clinical rheumatologist and Inmedix CEO & Co-founder. “We believe ANS stress profile may be an overlooked, cost-effective and immediately actionable element of personalized, precision medicine able to significantly improve clinical outcomes for patients with autoimmune diseases.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd. are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress, modulated within the brain by the autonomic nervous system (ANS). The Inmedix ANS Neuroscan™ is leading the development of applications of next-generation heart rate variability (HRV) as a potentially informative diagnostic, therapeutic, digital health and health economic tool in autoimmune disease. ANS profile may be the most overlooked element of personalized, precision medicine. Beginning with rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS) and multiple sclerosis (MS) in adults, the company hopes to enhance current therapeutic outcomes through complimentary optimization of individual ANS profile.

NOTICE:

This press release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation progress of development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Rae Marie Gleason
Education Program Director, Inmedix, Inc.
714-423-4863
email us here


Source: EIN Presswire